TRIKAFTA tablets. FDA-Approved. To treat cystic fibrosis (CF)

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

TRIKAFTA is a prescription medicine. TRIKAFTA is used to treat cystic fibrosis (CF).
INDICATIONS AND USAGE
TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
DOSAGE FORMS & STRENGTHS

Tablets: fixed dose combination containing elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg.
Co-packaged with: • Tablets: ivacaftor 150 mg.

Manufactured By: Vertex Pharmaceuticals Incorporated
Prescribing Information URL: Click Here

South Delhi Pharma facilitate the supply of “TRIKAFTA FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.

Category Lung Cancer

Category Lung Cancer

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Note: Notice for Sourcing Inquiries

Description

Description

Elexacaftor/tezacaftor/ivacaftor, sold under the brand name Trikafta, is a fixed-dose combination medication used in those that have cystic fibrosis with a f508del mutation. It is made up of a combination of elexacaftor, tezacaftor, and ivacaftor.

It was approved for medical use in the United States in 2019.

In June 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended the approval of elexacaftor/tezacaftor/ivacaftor (Kaftrio) for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.